search
Back to results

IDEA Study Cognitive Stimulation Therapy (CST) Trial in Nigeria (IDEA)

Primary Purpose

Dementia

Status
Completed
Phase
Not Applicable
Locations
Nigeria
Study Type
Interventional
Intervention
CST intervention
Sponsored by
William Keith Gray
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Dementia focused on measuring Dementia, Cognitive Stimulation Therapy, Quality of life, Cognitive impairment, Africa, Tanzania, Nigeria, Low- and Middle-income countries, Non-pharmacological intervention, Task-shifting, Cognitive screening

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Anyone with dementia living within the study site

Exclusion Criteria:

  • The participant and the family should have consented to take part in the study.
  • Unable to travel to the centre where the CST sessions will be held due to physical impairment (e.g. bedbound or immobile)
  • After assessment by the study doctor, deemed unable to engage in CST sessions (e.g. follow instructions and participate in activities) due to severe physical or cognitive impairment.
  • Profound deafness
  • Total blindness
  • Aphasia - they should be able to understand verbal communication and communicate verbally (mild impairments are acceptable).
  • The participant should be able to sit in a group setting for 1 hour.
  • There should not be agitation, depression or psychosis to an extent that the person would not be able to tolerate spending time with other people in a group setting

Sites / Locations

  • Lalupon

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CST intervention

Arm Description

Outcomes at baseline will be compared with those immediately post intervention and at four weeks post-intervention. In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. The investigators will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location. Individuals will be allocated to groups based on religion, gender and geographical location.

Outcomes

Primary Outcome Measures

World Health Organization Brief Quality of Life Measure (WHOQOL-Bref)
Quality of life assessment in patients and carers. The minimum score is 4 and the maximum 20, with a higher score signifying better quality of life.
World Health Organization Brief Quality of Life Measure (WHOQOL-Bref)
Quality of life assessment in patients and carers. The minimum score is 4 and the maximum 20, with a higher score signifying better quality of life.

Secondary Outcome Measures

WHOQOL Bref
Quality of life assessment in patients and carers. The minimum score is 4 and the maximum 20, with a higher score signifying better quality of life.
IDEA Cognitive Screen
Cognitive assessment in patients
IDEA Cognitive Screen
Cognitive assessment in patients
IDEA Cognitive Screen
Cognitive assessment in patients
Hospital Anxiety and Depression Scale (HADS)
Anxiety and depression assessment in patients and carers. The minimum score is 0 and the maximum 42, with a higher score signifying greater depression.
Hospital Anxiety and Depression Scale (HADS)
Anxiety and depression assessment in patients and carers. The minimum score is 0 and the maximum 42, with a higher score signifying greater depression.
Hospital Anxiety and Depression Scale (HADS)
Anxiety and depression assessment in patients and carers
Zarit Burden Interview (ZBI)
Carer burden assessment. The minimum score is 0 and the maximum 48, with a higher score signifying greater carer burden.
Zarit Burden Interview (ZBI)
Carer burden assessment. The minimum score is 0 and the maximum 48, with a higher score signifying greater carer burden.
Zarit Burden Interview (ZBI)
Carer burden assessment
Adapted Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)
Cognitive assessment in patients. The minimum score is 0 and the maximum 70, with a lower score signifying better cognition.
Adapted Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)
Cognitive assessment in patients. The minimum score is 0 and the maximum 70, with a lower score signifying better cognition.
Adapted Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)
Cognitive assessment in patients
Study Specific Economic Evaluation
Assessment of health service utilisation and time and travel for patients and carers
Study Specific Economic Evaluation
Assessment of health service utilisation and time and travel for patients and carers

Full Information

First Posted
August 30, 2014
Last Updated
May 26, 2021
Sponsor
William Keith Gray
Collaborators
Grand Challenges Canada, University of Ibadan, Kilimanjaro Christian Medical Centre, Tanzania, Newcastle University, Northumbria Healthcare NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT02233530
Brief Title
IDEA Study Cognitive Stimulation Therapy (CST) Trial in Nigeria
Acronym
IDEA
Official Title
Identification and Intervention for Dementia in Elderly Africans (IDEA) Study: CST Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
September 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
William Keith Gray
Collaborators
Grand Challenges Canada, University of Ibadan, Kilimanjaro Christian Medical Centre, Tanzania, Newcastle University, Northumbria Healthcare NHS Foundation Trust

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This trials of cognitive stimulation therapy (CST) in Tanzania is part of the larger Identification and Intervention for Dementia in Elderly Africans (IDEA) study. The overall aim of the IDEA study is to set up and evaluate sustainable programmes to facilitate diagnosis of, and therapy for, people with dementia led by local communities in sub-Saharan Africa. The investigators seek to improve quality of life for people with dementia and their caregivers. Within this trial of CST, the investigators hypothesise that CST can significantly improve the quality of people with dementia and their carers living in Africa
Detailed Description
The project will address three specific challenges: 1) Integrate screening and core packages of services into routine primary health care. 2) Provide effective and affordable community-based care and rehabilitation. 3) Develop effective treatment for use by non-specialists, including lay healthcare workers with minimal training. Dementia is under-diagnosed in sub-Saharan Africa (SSA) and treatment is rarely accessed or available. The burden of dementia on caregivers is high, with loss of income, and psychosocial stress common. However, large scale screening for dementia in such a setting is neither affordable nor sustainable. The purpose of this 3 year project is to provide a sustainable mechanism for diagnosis and therapeutic intervention for people with dementia. The investigators will use 2 complimentary, rural study sites, 1 in Nigeria, West Africa and 2 in Tanzania, East Africa. As a consequence our results should be generalizable to all SSA. Our approach is inexpensive and will have applicability to other low- and middle-income countries. During Phase I the investigators will validate a screening tool, previously developed by members of our study team from data collected in Tanzania, and carry out a pilot study of the benefits of cognitive stimulation therapy (CST) when used in SSA for those already identified with dementia. During both of these activities the investigators will initiate training of local healthcare workers in diagnosis and management of people with dementia. In Phase II the investigators will engage with local communities to raise awareness of dementia. Building on previous work at both study sites, the investigators will initiate poster, newspaper and radio advertising and use mobile phone text messaging services (for relevant healthcare personnel) to increase awareness of the need to diagnose and intervene at an early stage. The investigators will empower local private pharmacies to help identify people with dementia, a relationship which will ultimately be mutually beneficial through the supply of medicines to treat risk factors for dementia, such as hypertension. The investigators will engage with local community leaders and government officials to assist us in this awareness raising, an approach that has proven successful in previous studies by our team in SSA. One of our study team (Dr Mushi (DM)) is a social scientist based in Tanzania and during Phase II the investigators will conduct qualitative research into attitudes and beliefs surrounding dementia and identify any barriers to diagnosis in both sites. The results of this research will be fed back to inform other phases of the study. Finally, in phase III the investigators will initiate a program of community based CST led by local occupational therapists (OTs) and nurse specialists. OTs and nurses will train caregivers in CST techniques and the investigators hope that the training will ultimately be led by caregivers allowing such therapy to become sustainable within communities in the longer term. The investigators will evaluate changes in cognition in people with dementia, and quality of life (QOL) in both people with dementia and their caregivers, post-intervention. The investigators will carry out a full economic evaluation of the effect of our program, to be led by a heath economist based at Newcastle University, United Kingdom. This protocol cover the CST trial (Phase III of the study) in Nigeria

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dementia
Keywords
Dementia, Cognitive Stimulation Therapy, Quality of life, Cognitive impairment, Africa, Tanzania, Nigeria, Low- and Middle-income countries, Non-pharmacological intervention, Task-shifting, Cognitive screening

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CST intervention
Arm Type
Experimental
Arm Description
Outcomes at baseline will be compared with those immediately post intervention and at four weeks post-intervention. In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. The investigators will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location. Individuals will be allocated to groups based on religion, gender and geographical location.
Intervention Type
Behavioral
Intervention Name(s)
CST intervention
Intervention Description
The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
Primary Outcome Measure Information:
Title
World Health Organization Brief Quality of Life Measure (WHOQOL-Bref)
Description
Quality of life assessment in patients and carers. The minimum score is 4 and the maximum 20, with a higher score signifying better quality of life.
Time Frame
Baseline
Title
World Health Organization Brief Quality of Life Measure (WHOQOL-Bref)
Description
Quality of life assessment in patients and carers. The minimum score is 4 and the maximum 20, with a higher score signifying better quality of life.
Time Frame
An average of eight weeks from baseline
Secondary Outcome Measure Information:
Title
WHOQOL Bref
Description
Quality of life assessment in patients and carers. The minimum score is 4 and the maximum 20, with a higher score signifying better quality of life.
Time Frame
An average of twelve weeks from baseline
Title
IDEA Cognitive Screen
Description
Cognitive assessment in patients
Time Frame
Baseline
Title
IDEA Cognitive Screen
Description
Cognitive assessment in patients
Time Frame
An average of eight weeks from baseline
Title
IDEA Cognitive Screen
Description
Cognitive assessment in patients
Time Frame
An average of twelve weeks from baseline
Title
Hospital Anxiety and Depression Scale (HADS)
Description
Anxiety and depression assessment in patients and carers. The minimum score is 0 and the maximum 42, with a higher score signifying greater depression.
Time Frame
Baseline
Title
Hospital Anxiety and Depression Scale (HADS)
Description
Anxiety and depression assessment in patients and carers. The minimum score is 0 and the maximum 42, with a higher score signifying greater depression.
Time Frame
An average of eight weeks from baseline
Title
Hospital Anxiety and Depression Scale (HADS)
Description
Anxiety and depression assessment in patients and carers
Time Frame
An average of twelve weeks from baseline
Title
Zarit Burden Interview (ZBI)
Description
Carer burden assessment. The minimum score is 0 and the maximum 48, with a higher score signifying greater carer burden.
Time Frame
Baseline
Title
Zarit Burden Interview (ZBI)
Description
Carer burden assessment. The minimum score is 0 and the maximum 48, with a higher score signifying greater carer burden.
Time Frame
An average of eight weeks from baseline
Title
Zarit Burden Interview (ZBI)
Description
Carer burden assessment
Time Frame
An average of twelve weeks from baseline
Title
Adapted Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)
Description
Cognitive assessment in patients. The minimum score is 0 and the maximum 70, with a lower score signifying better cognition.
Time Frame
Baseline
Title
Adapted Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)
Description
Cognitive assessment in patients. The minimum score is 0 and the maximum 70, with a lower score signifying better cognition.
Time Frame
An average of eight weeks from baseline
Title
Adapted Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)
Description
Cognitive assessment in patients
Time Frame
An average of twelve weeks from baseline
Title
Study Specific Economic Evaluation
Description
Assessment of health service utilisation and time and travel for patients and carers
Time Frame
Baseline
Title
Study Specific Economic Evaluation
Description
Assessment of health service utilisation and time and travel for patients and carers
Time Frame
An average of twelve weeks from baseline

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Anyone with dementia living within the study site Exclusion Criteria: The participant and the family should have consented to take part in the study. Unable to travel to the centre where the CST sessions will be held due to physical impairment (e.g. bedbound or immobile) After assessment by the study doctor, deemed unable to engage in CST sessions (e.g. follow instructions and participate in activities) due to severe physical or cognitive impairment. Profound deafness Total blindness Aphasia - they should be able to understand verbal communication and communicate verbally (mild impairments are acceptable). The participant should be able to sit in a group setting for 1 hour. There should not be agitation, depression or psychosis to an extent that the person would not be able to tolerate spending time with other people in a group setting
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adesola Ogunniyi, MD
Organizational Affiliation
University of Ibadan, Nigeria
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Akin Adebiyi
Organizational Affiliation
University of Ibadan
Official's Role
Study Director
Facility Information:
Facility Name
Lalupon
City
Lalupon
State/Province
Oyo State
Country
Nigeria

12. IPD Sharing Statement

Citations:
PubMed Identifier
24578459
Citation
Gray WK, Paddick SM, Kisoli A, Dotchin CL, Longdon AR, Chaote P, Samuel M, Jusabani AM, Walker RW. Development and Validation of the Identification and Intervention for Dementia in Elderly Africans (IDEA) Study Dementia Screening Instrument. J Geriatr Psychiatry Neurol. 2014 Jun;27(2):110-8. doi: 10.1177/0891988714522695. Epub 2014 Feb 26.
Results Reference
background

Learn more about this trial

IDEA Study Cognitive Stimulation Therapy (CST) Trial in Nigeria

We'll reach out to this number within 24 hrs